
RA Capital
About
RA Capital Management® (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital® to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas.
Key facts
- Website
- racap.com
- Type
- Venture Capital
- Headquarters
- United States
- Portfolio companies
- 48
- Cheque size
- $22M to $220M
- Sector focus
- HealthcareLungBladderCancerDiagnostics
Recent investments
| Date | Company | Round | Amount |
|---|---|---|---|
| 1 Nov 2026 | Alethio Therapeutics | Series A | $90M |
| 15 Oct 2026 | Estuary Biotherapeutics | Series A | $93M |
| 18 Aug 2026 | Abcuro | Series D | $66M |
| 1 Jul 2026 | Alchemab Therapeutics | Series A | $32M |
| 2 Jun 2026 | Contraline | Series B | $93M |
| 6 May 2026 | CellCentric | Series D | $220M |
| 15 Apr 2026 | Terremoto Biosciences | Series C | $108M |
| 5 Jan 2022 | Nucleix | Funding Round | $22M |
| 7 Apr 2021 | Nucleix | Funding Round | $55M |
| 3 Feb 2021 | Freenome | Series D | $300M |
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
What companies has RA Capital invested in?
RA Capital has invested in Alethio Therapeutics, Estuary Biotherapeutics, Abcuro, Alchemab Therapeutics, Contraline and 43 more.
SEC filings, insider activity, nonprofit links and pay benchmarks for RA Capital:


